STRONGPOINT
23.6.2021 08:02:07 CEST | Business Wire | Press release
StrongPoint ASA , a leading European grocery retail solution provider, today announces its grocery e-commerce picking solution, designed specifically for grocery retailers looking for fast, hyper-efficient and scalable e-commerce logistics solutions. The Strongpoint solution suite delivers industry-leading efficiency rates with many in-store associates averaging ~240 items picked per labor hour across all product categories, compared with common industry standards of 60-65 items per hour.
Hosted on StrongPoint’s cloud-based SaaS e-commerce platform, the Order Picking solution helps retailers capitalize on the growing opportunity of online grocery, driving greater efficiency and higher productivity rates. It also reduces labor costs associated with the fulfillment of online orders, while enhancing customer convenience and protecting margins.
StrongPoint launched its first Order Picking solution more than 20 years ago. Since then, it has undergone countless iterations, changes and updates based on customer feedback over two decades of usage by thousands of pickers in multiple countries. A key benefit of StrongPoint’s cloud-based solution is that grocery retailers receive continuous updates as the team finds new opportunities to drive efficiency gains.
Since the start of the pandemic, Bain estimates adoption of online grocery in the US and Western Europe has accelerated between two and five years and this sustained demand is set to continue2 . Despite the explosion in demand, both for grocery e-commerce and q-commerce, retailers have struggled to make online grocery profitable, with the high cost of labor hours allocated to picking and the fulfillment of e-commerce orders ebbing away at already squeezed margins.
StrongPoint’s solution was born out of 35+ years’ experience in responding to the rapidly evolving needs of leading grocery retailers across multiple European countries. Its grocery e-commerce Order Picking solution delivers unprecedented efficiencies compared to orders that are picked manually, by empowering staff with its proprietary software technology.
Many of StrongPoint’s grocery retail customers who are utilizing the full functionalities of the solution are able to reach average in-store picking rates of ~240 items per labor hour across all product categories, compared with a common industry standard of 60-65 items per labor hour when using traditional solutions. In addition, StrongPoint’s Order Picking solution averages 99.99% accuracy, making it on par with leading fully automated grocery fulfillment solutions.
Its hyper-efficient orchestration technology customizes the picking route for the store associate, creating the most effective order sequencing for picking, based on the unique layout and footprint of each store. Other standard features include picking by temperature zones, multiple solutions for age-restricted items and substitution options.
The solution, which can be deployed in large and small format settings with the option of using Zebra hardware devices for maximum efficiency, includes multi-zone and multi-order picking capabilities to drive even greater efficiencies. It can integrate with in-built store hardware, such as electronic shelf labels (ESLs), allowing store associates to “pick to light” to increase speed and order accuracy. In addition, there is the option of integrating a smart trolley that has been purpose-built for maximum ergonomic efficiency. Data inputs at each stage of the picking process – from preparing the trolley to the picking, weighing, and bagging of products – create a continuous feedback loop, so ergonomic improvements can be made to drive further efficiencies, speed and accuracy.
“We are proud to unveil our latest technology solution, specifically designed to help grocery retailers leverage their stores and cater to the exponential growth of e-commerce,” said Jacob Tveraabak, CEO at StrongPoint. “Having worked with grocery retailers for over three decades, we understand the importance of driving speed, efficiency and scalability across their operations in the stores – and that was intrinsic in how we developed the latest iteration of our grocery e-commerce Order Picking solution.”
-ENDS-
Notes to editors
StrongPoint is a retail technology company that provides solutions to make shops smarter, shopping experiences better and online grocery shopping more efficient.
With over 450 employees in Norway, Sweden, the Baltics and Spain and, together with a wide partner network, StrongPoint supports businesses in more than 20 countries.
StrongPoint is headquartered in Norway and is listed on the Oslo Stock Exchange.
For more information, visit https://www.strongpoint.com/
1
https://www.mwpvl.com/MWPVL_International_-_Micro_Fulfillment_Centers_-_Passing_Fad_or_Permanent_Market_Shift.pdf
2
https://www.bain.com/insights/the-next-five-years-in-online-grocery-snap-chart/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005819/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
